European Commission Approves Pfizer’s HYMPAVZI (marstacimab) for the Treatment of Adults and…
Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for HYMPAVZI (marstacimab) for the routine prophylaxis of bleeding episodes in patients 12…
Read More...
Read More...
